FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079517811> ?p ?o ?g. }

• W2079517811 endingPage "1432" @default.
• W2079517811 startingPage "1423" @default.
• W2079517811 abstract "In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy. We measured levels of BCR-ABL transcripts in the blood of all patients in this trial who had a complete cytogenetic remission.Levels of BCR-ABL transcripts were measured by a quantitative real-time polymerase-chain-reaction assay. Results were expressed relative to the median level of BCR-ABL transcripts in the blood of 30 patients with untreated CML in chronic phase.In patients who had a complete cytogenetic remission, levels of BCR-ABL transcripts after 12 months of treatment had fallen by at least 3 log in 57 percent of those in the imatinib group and 24 percent of those in the group given interferon plus cytarabine (P=0.003). On the basis of the rates of complete cytogenetic remission of 68 percent in the imatinib group and 7 percent in the group given interferon plus cytarabine at 12 months, an estimated 39 percent of all patients treated with imatinib but only 2 percent of all those given interferon plus cytarabine had a reduction in BCR-ABL transcript levels of at least 3 log (P<0.001). For patients who had a complete cytogenetic remission and a reduction in transcript levels of at least 3 log at 12 months, the probability of remaining progression-free was 100 percent at 24 months, as compared with 95 percent for such patients with a reduction of less than 3 log and 85 percent for patients who were not in complete cytogenetic remission at 12 months (P<0.001).The proportion of patients with CML who had a reduction in BCR-ABL transcript levels of at least 3 log by 12 months of therapy was far greater with imatinib treatment than with treatment with interferon plus cytarabine. Patients in the imatinib group with this degree of molecular response had a negligible risk of disease progression during the subsequent 12 months." @default.
• W2079517811 created "2016-06-24" @default.
• W2079517811 creator A5004837780 @default.
• W2079517811 creator A5011454613 @default.
• W2079517811 creator A5020401806 @default.
• W2079517811 creator A5032196793 @default.
• W2079517811 creator A5035964802 @default.
• W2079517811 creator A5059558422 @default.
• W2079517811 creator A5066398043 @default.
• W2079517811 creator A5080880463 @default.
• W2079517811 creator A5085532556 @default.
• W2079517811 creator A5089541690 @default.
• W2079517811 creator A5091006472 @default.
• W2079517811 date "2003-10-09" @default.
• W2079517811 modified "2023-10-14" @default.
• W2079517811 title "Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia" @default.
• W2079517811 cites W1483173437 @default.
• W2079517811 cites W1540355515 @default.
• W2079517811 cites W1582339002 @default.
• W2079517811 cites W1604672566 @default.
• W2079517811 cites W1989957533 @default.
• W2079517811 cites W2006917576 @default.
• W2079517811 cites W2011474502 @default.
• W2079517811 cites W2016086822 @default.
• W2079517811 cites W2028959752 @default.
• W2079517811 cites W2032164085 @default.
• W2079517811 cites W2040396943 @default.
• W2079517811 cites W2049426761 @default.
• W2079517811 cites W2049611823 @default.
• W2079517811 cites W2058558811 @default.
• W2079517811 cites W2076372887 @default.
• W2079517811 cites W2081251682 @default.
• W2079517811 cites W2091849791 @default.
• W2079517811 cites W2097255369 @default.
• W2079517811 cites W2103072940 @default.
• W2079517811 cites W2117782490 @default.
• W2079517811 cites W2117806883 @default.
• W2079517811 cites W2128738046 @default.
• W2079517811 cites W2142969636 @default.
• W2079517811 cites W2161348772 @default.
• W2079517811 cites W2171722798 @default.
• W2079517811 cites W2258838187 @default.
• W2079517811 cites W2329648702 @default.
• W2079517811 cites W2337277825 @default.
• W2079517811 cites W2394816133 @default.
• W2079517811 cites W2401486119 @default.
• W2079517811 cites W2508058084 @default.
• W2079517811 cites W4235132465 @default.
• W2079517811 cites W4235384912 @default.
• W2079517811 cites W4237680481 @default.
• W2079517811 cites W68935899 @default.
• W2079517811 doi "https://doi.org/10.1056/nejmoa030513" @default.
• W2079517811 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14534335" @default.
• W2079517811 hasPublicationYear "2003" @default.
• W2079517811 type Work @default.
• W2079517811 sameAs 2079517811 @default.
• W2079517811 citedByCount "1181" @default.
• W2079517811 countsByYear W20795178112012 @default.
• W2079517811 countsByYear W20795178112013 @default.
• W2079517811 countsByYear W20795178112014 @default.
• W2079517811 countsByYear W20795178112015 @default.
• W2079517811 countsByYear W20795178112016 @default.
• W2079517811 countsByYear W20795178112017 @default.
• W2079517811 countsByYear W20795178112018 @default.
• W2079517811 countsByYear W20795178112019 @default.
• W2079517811 countsByYear W20795178112020 @default.
• W2079517811 countsByYear W20795178112021 @default.
• W2079517811 countsByYear W20795178112022 @default.
• W2079517811 countsByYear W20795178112023 @default.
• W2079517811 crossrefType "journal-article" @default.
• W2079517811 hasAuthorship W2079517811A5004837780 @default.
• W2079517811 hasAuthorship W2079517811A5011454613 @default.
• W2079517811 hasAuthorship W2079517811A5020401806 @default.
• W2079517811 hasAuthorship W2079517811A5032196793 @default.
• W2079517811 hasAuthorship W2079517811A5035964802 @default.
• W2079517811 hasAuthorship W2079517811A5059558422 @default.
• W2079517811 hasAuthorship W2079517811A5066398043 @default.
• W2079517811 hasAuthorship W2079517811A5080880463 @default.
• W2079517811 hasAuthorship W2079517811A5085532556 @default.
• W2079517811 hasAuthorship W2079517811A5089541690 @default.
• W2079517811 hasAuthorship W2079517811A5091006472 @default.
• W2079517811 hasBestOaLocation W20795178111 @default.
• W2079517811 hasConcept C104317684 @default.
• W2079517811 hasConcept C125418893 @default.
• W2079517811 hasConcept C126322002 @default.
• W2079517811 hasConcept C138626823 @default.
• W2079517811 hasConcept C143998085 @default.
• W2079517811 hasConcept C170493617 @default.
• W2079517811 hasConcept C203014093 @default.
• W2079517811 hasConcept C2776178377 @default.
• W2079517811 hasConcept C2777583451 @default.
• W2079517811 hasConcept C2778041864 @default.
• W2079517811 hasConcept C2778461978 @default.
• W2079517811 hasConcept C2778729363 @default.
• W2079517811 hasConcept C2778904597 @default.
• W2079517811 hasConcept C2781228144 @default.
• W2079517811 hasConcept C2909179924 @default.
• W2079517811 hasConcept C3019892230 @default.

• next